Abstract
Background. Adjuvant chemotherapy after preoperative treatment and curative resection for rectal cancer is the standard of care in several and European and US guidelines. However, no clear survival benefit has been shown for stage II/III rectal cancer patients, and the influence of adjuvant chemotherapy on health-related quality of life (HR-QOL) is unknown. In this study we aimed to examine the differences in HR-QOL over time between patients with rectal cancer treated with adjuvant chemotherapy and observation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
